Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURACVE:GPHNYSEMKT:IGCNASDAQ:ORPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.04+2.5%$5.73$4.35▼$12.38$303.63M0.43210,217 shs70,656 shsGPHGraphite OneC$0.88+12.8%C$0.87C$0.55▼C$1.07C$89.10M1.0263,898 shs290,097 shsIGCIGC Pharma$0.33+1.8%$0.30$0.25▼$0.55$26.85M1.5338,482 shs214,616 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences0.00%-0.51%+9.48%-19.09%-16.22%GPHGraphite One0.00%-1.27%-15.22%-18.75%-8.24%IGCIGC Pharma0.00%+9.80%+13.13%+21.30%+33,599,900.00%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAURAAura Biosciences2.6227 of 5 stars3.62.00.00.03.23.30.0GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AIGCIGC Pharma1.6995 of 5 stars3.50.00.00.02.41.70.0ORPHOrphazyme A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 3.25Buy$22.75276.66% UpsideGPHGraphite One 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.881,067.17% UpsideORPHOrphazyme A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ORPH, GPH, IGC, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.003/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.003/24/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/6/2025IGCIGC PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.50(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AIGCIGC Pharma$1.24M21.40N/AN/A$0.08 per share4.15ORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$76.41M-$1.90N/AN/AN/AN/A-41.57%-36.43%8/14/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AIGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/AORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/ALatest ORPH, GPH, IGC, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A12.4712.47GPHGraphite One0.021.090.33IGCIGC Pharma0.021.150.98ORPHOrphazyme A/S0.141.80N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%GPHGraphite One0.07%IGCIGC Pharma3.87%ORPHOrphazyme A/S10.74%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences5.40%GPHGraphite One28.81%IGCIGC Pharma31.48%ORPHOrphazyme A/SN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5050.27 million47.25 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableIGCIGC Pharma6179.69 million54.60 millionN/AORPHOrphazyme A/S14135.31 millionN/ANot OptionableORPH, GPH, IGC, and AURA HeadlinesRecent News About These CompaniesHow Four Sigmatic Made Mushrooms A Multi-Billion Dollar CategoryNovember 11, 2024 | forbes.comWeight loss care is leading IPO-hopeful Omada Health's latest growth surge as Ozempic boom continuesOctober 30, 2024 | businessinsider.comIncyte’s Strong Financial Performance and Promising Pipeline Lead to Buy RatingOctober 30, 2024 | markets.businessinsider.comOzempic could help reduce Alzheimer’s risk for some, study suggests: ‘Shifting the paradigm’October 26, 2024 | msn.comAquestive Therapeutics’ Favorable OAS Study Boosts Anaphylm’s Prospects with Raised Price Target and Buy RatingOctober 25, 2024 | markets.businessinsider.comOzempic linked to lower risk of Alzheimer’s diagnosis in observational studyOctober 24, 2024 | statnews.comPharmalittle: We’re reading about drug shortages, what drugmakers didn’t tell Alzheimer’s trial patients and moreOctober 24, 2024 | statnews.comNovo’s Ozempic Linked to Reduced Alzheimer’s DiagnosesOctober 24, 2024 | msn.comHow Europe's Biggest Buyout Deal Descended Into a Bruising BrawlOctober 24, 2024 | bloomberg.comNasdaq Welcomes Strategic Partners A/S to Nasdaq Copenhagen Main MarketOctober 24, 2024 | finanznachrichten.deUK regulator approves second Alzheimer's drug in months but government won't pay for itOctober 23, 2024 | abcnews.go.comFDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 YearsOctober 23, 2024 | benzinga.comFDA approves Pfizer's RSV shot Abrysvo for all at-risk adultsOctober 23, 2024 | fiercepharma.comArtiphon’s new Orba instrument can sample sounds liveOctober 22, 2024 | techcrunch.comInjectable drug to ease advanced Parkinson's disease symptoms approved by FDAOctober 17, 2024 | msn.com3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy VyalevOctober 17, 2024 | fiercepharma.comUS FDA expands approval for Avadel's sleep disorder drugOctober 17, 2024 | msn.comJ&J Scraps Pipeline Assets Including Alzheimer’s and Parkinson’s CandidatesOctober 17, 2024 | biospace.comTop six European biotech entrepreneurs to know in 2024 (according to VCs)October 17, 2024 | labiotech.euFDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And AdolescentsOctober 12, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORPH, GPH, IGC, and AURA Company DescriptionsAura Biosciences NASDAQ:AURA$6.04 +0.15 (+2.55%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Graphite One CVE:GPHC$0.88 +0.10 (+12.82%) As of 02:04 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.IGC Pharma NYSEMKT:IGC$0.33 +0.01 (+1.81%) As of 02:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Orphazyme A/S NASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Scores First $1 Billion Contract; Is It Priced In? Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down its Tech and Outlook MarketBeat Week in Review – 05/19 - 05/23 Workday Stock Price Implosion: An Automatic Buy for AI Investors Can Ross Stores Be the Safety Cushion In Retail Stocks? MercadoLibre Is Soaring—Should You Wait for a Better Entry? Trade Desk Silences Critics; Recovery Looks Poised to Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
